CommercialCoverageMedium impact
Gene Expression Profiling for Cutaneous Melanoma 2.02.52
Excellus BlueCross BlueShield·Dermatology, Oncology, Pathology·Cancer Treatment (Oncology)
Effective date
Oct 16, 2025
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield has updated their policy classifying all gene expression profiling (GEP) tests for melanoma evaluation as investigational and non-covered, including PLA, MyPath Melanoma, DecisionDx Melanoma, and DecisionDx DiffDx-Melanoma tests. This policy is effective October 16, 2025, meaning claims for these genetic tests will be denied.
Action Required
By October 16, 2025: Billing team must update systems to flag all melanoma gene expression profiling tests (PLA, MyPath Melanoma, DecisionDx Melanoma, DecisionDx DiffDx-Melanoma) as non-covered for Excellus BlueCross BlueShield members. Notify providers that these tests are considered investigational and claims will be denied. Update encounter forms and EMR alerts to prevent ordering these tests without patient financial responsibility discussions.